Candice Gwiazdowski – Trademark Portfolio

Entity Type: 01

Candice Gwiazdowski holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include RIKO and RIKO & CO. The owner is based in Carlsbad, CA.

4769 Edinburgh Dr

Carlsbad, CA 92010

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

RIKO
RIKO
Registered 2025
RIKO & CO
RIKO & CO
Registered 2024

Trademark Classifications

Candice Gwiazdowski's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

16
Paper Goods (1 filing)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

Frequently Asked Questions

How many trademarks does Candice Gwiazdowski have?

Candice Gwiazdowski has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 cancelled.

What trademark classes does Candice Gwiazdowski file in?

Candice Gwiazdowski files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Candice Gwiazdowski's most well-known trademarks?

Candice Gwiazdowski's registered trademark portfolio includes well-known marks such as RIKO and RIKO & CO. These are among 2 currently registered trademarks in the portfolio.

What is Candice Gwiazdowski's trademark registration success rate?

Candice Gwiazdowski has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.